Updated Prostate Cancer Screening Guidelines Announced
Shared decision-making about screening recommended for men aged 55-69 years.
Shared decision-making about screening recommended for men aged 55-69 years.
Median survival time from diagnosis improved by a median of 43 months from the pre-PSA to the post-PSA era.
In fact, men on testosterone replacement therapy (TRT) had a lower PCa rate than men not on TRT.
Data support prophylactic use of a PDE-5 inhibitor in men receiving radiotherapy for prostate cancer.
This approach can reduce adverse events without impairing efficacy.
Study finds a significant inverse association between weight changes and incontinence scores in normal-weight patients.
New findings underscore the importance of achieve maximal tumor control in patients with high-risk disease.
Patients with pT4 tumors had five-year cancer-specific and overall survival rates of 91%.
After more than 10 years of follow-up, 54% of patients progressed, but only one patient died from prostate cancer.
Study reveals an elevated risk of lung cancer, which researchers called an intriguing finding.
Please login or register first to view this content.